Monoclonal Antibody Therapies and Neurologic Disorders
Arch Neurol 65:1162-1165, Novack,J.C.,et al., 2008
Maternal and Fetal Risks of Natalizumab Exposure in Utero
Neurol 90:443-444, Marrie, R.A.,et al, 2018
Varicella-Zoster Virus Acute Myelitis in a Patient with MS Treated with Natalizumab
Neurol 80:1812-1813, Yeung, J.,et al, 2013
Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy
Neurol 76:1697-1704, Vermersch,P.,et al, 2011
Management and Outcome of CSF-JC Virus PCR-negative PML in a Natalizumab-treated Patient with MS
Neurol 77:2010-2016, Kuhle, J.,et al, 2011
Natalizumab Treatment in a Patient With Chronic Inflammatory Demyelinating Polyneuropathy
Arch Neurol 67:881-883, Wolf,C., et al, 2010
Progressive Multifocal Leukoencephalopathy and Relapsing-Remitting Multiple Sclerosis: A Comparative Study
Arch Neurol 66:593-599, Boster,A.,et al, 2009
Progressive Multifocal Leukoencephalopathy Revisited: Has the Disease Outgrown Its Name?
Ann Neurol 60:162-173, Koralnik,I.J., 2006
Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis
NEJM 353:369-374,414,432, Kleinschemidt-DeMasters,B.K. &Tyler,K.L., 2005